Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Cinclus Pharma: First patient screened for the phase III study - Redeye

Analys | Redeye

•

I förrgår 15:32

Cinclus Pharma: First patient screened for the phase III study - Redeye

Biovica Q1 Update: Capitalised but the launch is still not in full swing - Redeye

Biovica continues to increase 12m rolling IVD test sales in Q1 of SEK 0.

Guard Therapeutics: Data collection in phase IIb study POINTER completed - Redeye

Scibase: Positive ownership changes - Redeye

Yesterday, Scibase announced that Ribbskottet AB and Life Science Investment Fund (LSIF), have each ...

Hexatronic: Acquisitions outside of FTTH to fuel growth - Redeye

Acarix: Increased shareholding by CEO - Redeye

Redeye comments on Acarix following recent news relating to the ownership structure, where, among ot...

Thunderful Group: We expect Atari aims for strategic “retro-synergies” - Redeye

Miris: Tydliga steg mot lönsamhet - Mangold Insight Analys

Mangold uppdaterar sin syn på medicinteknik-bolaget Miris.

Biovica: Preparing to activate US channels for clinical use of DiviTum - Redeye

Hexatronic: New targets and cost savings – confirming softened long-term FTTH outlook - Redeye

Redeye makes an initial comment about the new targets and cost savings.

Guard Therapeutics: A binary case with asymmetric upside - Redeye

OncoZenge: Appoints LINK Medical as CRO for the phase III study - Redeye

Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase ...

Smart Eye: Large AIS order from Optix - Redeye

Senzime: Updated clinical guidelines in Japan - Redeye

Redeye endorses the updated clinical guidelines in Japan supporting quantitative neuromuscular patie...

BioArctic: Strong momentum, fair price - Redeye

Endomines: Second chapter of the story begins - Evli

In May, Endomines unveiled its updated strategy for 2025–2029.

Litium: More Brains, More Geins - Redeye

Sprint Bioscience: A clear objective to secure a new partner - Redeye

With additional funds and a streamlined organisation, Sprint Bioscience continues to proactively pro...

Alligator Bioscience: New Clinical Study Funded - Redeye

SynAct Pharma: Warrant and Share Transaction - Redeye

Redeye views Hunter Capital's purchase of shares and warrants from Heights Capital Management as ope...

Q-linea: Two additional ASTar evaluations in the Middle East - Redeye

Litium: Acquiring Geins - Redeye

This morning, Litium announced the acquisition of Geins, a SaaS e-commerce platform with strong AI a...

Atria: China to impose EU pork imports temporary duties - Nordea

Acconeer: Design win with upside potential - Redeye

Acconeer has announced its A121 pulsed coherent radar has been selected by an additional Japanese ca...

Acconeer

Analys | Analysguiden

•

05 Sep 10:08

Cell Impact: Sval marknad - säkrad finansiering - Analysguiden

CLS: FDA clearance for 1.5T MRI guidance - Redeye

Redeye is positive about the FDA clearance to expand the labeling of the Prism system.

Clinical Laserthermia

Analys | Redeye

•

04 Sep 15:10

Alzinova: IND approval for phase II study - Redeye

Alzinova

Analys | Analysguiden

•

04 Sep 15:10

Botnia Gold: Starkt kassaflöde och resultat - Analysguiden

Botnia Gold redovisade ett starkt andra kvartal med intäkter på 115 Mkr och ett rörelseresultat på 4...

Sprint Biopharma: A clear objective to secure a new partner - Redeye

Senzime: Monitoring a growth story in progress - Redeye

Redeye initiates coverage of Senzime, a Swedish medtech company specialising in quantitative neuromu...

Senzime

Föregående Nästa